S&P Futures
4,018.75 +17.50 (+0.44%) Dow Futures
32,555.00 +121.00 (+0.37%) Nasdaq Futures
12,934.00 +43.75 (+0.34%) Russell 2000 Futures
1,757.40 +9.70 (+0.56%) Crude Oil
69.61 +0.35 (+0.51%) Gold
1,977.60 -6.20 (-0.31%)
After hours:
Chart Events
Performance Outlook
| Previous Close | 5.94 |
| Open | 6.00 |
| Bid | 5.76 x 900 |
| Ask | 6.21 x 1200 |
| Day's Range | 5.76 - 6.20 |
| 52 Week Range | 5.76 - 15.39 |
| Volume | |
| Avg. Volume | 578,136 |
| Market Cap | 511.095M |
| Beta (5Y Monthly) | 0.83 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences: Cowen 43rd Annual Health Care Conference (Boston, Massachusetts) Tuesday, March 7, 2023, at 10:30 a.m. ET, panel Stifel 2023 CNS Days (Virtual) Tuesday, March 28, 2023, at 12:00 p.m. ET, fireside chat A webcast of each conference presentatio
- GlobeNewswire
Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
On track to complete enrollment in the INVOKE-2 Phase 2 clinical trial of AL002 in patients with early Alzheimer’s disease in Q3 2023, with data readout expected by Q4 2024 Preparing to engage with regulatory authorities in mid-2023 and targeting data readout from the pivotal INFRONT-3 clinical trial for latozinemab in early 2025 pending regulatory feedback Additional data from the INFRONT-2 Phase 2 clinical trial of latozinemab in FTD-C9orf72 expected during the second half of 2023 Company and
- GlobeNewswire
Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today announced that on December 6, 2022, the compensation committee of Alector’s board of directors granted 8 (eight) new employees options to purchase an aggregate of 91,851 shares of the company’s common stock and restricted stock units (RSUs) for an aggregate of 40,961 shares of the company’s common stock.
